Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)

Figure 4

Pancreatic histology at the end of experimental period. Endocrine pancreas (a, b and c): (a) Typical islet from control ZDF ($+/+$) rats under vehicle treatment, without changes in the endocrine and exocrine pancreas; (b) Extensive fibrosis, vacuolation and loss of architecture in diabetic ZDF (fa/fa) rats under vehicle treatment; (c) Diminution in fibrosis intensity and vacuolation in Langerhans islet from diabetic ZDF (fa/fa) rats treated for 6 weeks with 10 mg/kg BW/day of sitagliptin, between weeks 20 and 26 (final time); Exocrine pancreas (d, e and f): (d) Severe fibrosis (III) with neocanaliculi (original magnification x 200) and (e) Congestion and intense inflammatory infiltrate from diabetic ZDF (fa/fa) rats treated with vehicle; (f) Marked decrease in fibrosis severity from diabetic ZDF (fa/fa) rats treated with sitagliptin. hematoxylin and eosin staining (original magnification x 400).